BPC-157: The Most Searched Peptide We Grade Has Never Been Tested in Humans

BPC-157 is the most searched compound in our graded library, at about 301,000 searches a month. It is also the clearest case in the library of demand running ahead of evidence, so the first line of this check is the whole finding: there are no published human trials of BPC-157. Not small ones, not flawed ones. None.

What it is, and where the claims come from

BPC-157 is a synthetic peptide fragment derived from a protein found in stomach juice. In animal studies, mostly in rats, it has shown effects on tissue repair, blood vessel growth, and gut healing. Online, it circulates as a healing compound for tendons, joints, and the gut, sometimes under the nickname "the Wolverine peptide." Products are sold as injections and capsules by online sellers.

The gap between the animal record and the human claims is where every BPC-157 claim lives. Animal data does not transfer to humans at any fixed rate, and for this compound the transfer has simply never been tested: no published human dose-finding, no human safety record, no human outcome data to check a claim against. Its grade in our library is D, with a worth-it grade of D at a typical $30 to $60 a month, because there is nothing human to grade up from.

The 2026 regulatory movement, and what it is not

Two things happened in 2026 that sellers cite as momentum. In February, an HHS announcement moved BPC-157 toward Category 1, the compounding-eligible category, which would let compounding pharmacies prepare it with a prescription. In July, the FDA's Pharmacy Compounding Advisory Committee voted to recommend it for the 503A Bulks List, a non-binding recommendation made over the objection of the agency's own scientists.

Neither event is FDA approval, and neither says anything about whether BPC-157 works. Compounding categories govern whether a pharmacy may prepare a substance. They are not efficacy findings, and in this case the advisory vote went against the reviewing scientists' position. A claim that regulators are "approving" BPC-157 takes two procedural steps and mislabels both.

What a reader can actually conclude

Three facts hold up. One, the animal literature is real and extensive, and it is the entire file. Two, the human safety picture is not reassuring or alarming; it is absent, and online products are unregulated, with unknown purity. Three, BPC-157 is banned by WADA, so competitive athletes risk a sanction for a compound with no human evidence behind it.

Our standing rule for compounds like this one is simple: it is never suggested here, only verdicted. If a human trial of BPC-157 publishes, the record will be re-graded on it. Until then, $30 to $60 a month buys a rat literature and a testimonial feed.

Grades are research summaries, not medical advice.